A novel splice site mutation in the COL4A5 gene in a Chinese female patient with rare ocular abnormalities

Chan Zhao,1 Fang Wang,2 Yanqin Zhang,2 Yubing Wen,2 Ying Su,3 Chengfen Zhang,1 Ruifang Sui,1 Fei Xu,1 Jie Ding,1 Fangtian Dong1

(The first two authors contributed equally to this work and both qualify as the first author)

1Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China; 2Department of Pediatrics, Peking University First Hospital, Beijing, P.R. China; 3Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P.R. China

Purpose: To describe an unusual ocular phenotype in a Chinese female patient with X-linked Alport syndrome (XLAS), and to characterize the type IV collagen alpha 5 (COL4A5) gene mutation in the patient and her son.

Methods: Detailed ophthalmologic examinations and optical coherence tomography were performed in the patient and her family members. For gene analysis of COL4A5, the entire coding region of COL4A5 mRNA from cultured skin fibroblast was analyzed by using reverse-transcription-polymerase chain reaction (RT–PCR) and direct sequencing, and genomic DNA was analyzed by using PCR and direct sequencing.

Results: The patient presented with progressive myopia at age 14 and bilateral giant macular holes (about 2 disc diameter) at age 28. At age 33 when presented to our hospital, slit lamp examination of the anterior segment showed bilateral anterior and posterior lenticonus; fundus photography and optical coherence tomography showed bilateral giant macular holes which were larger than photographed at age 28. Electron microscopy of renal biopsy showed irregular thinned and thickened areas of the glomerular basement membrane with splitting of the lamina densa. Her son was then found to have hematuria (at age 3), and indirect immunofluorescence of the epidermal basement membrane showed negative staining for the collagen α5(IV) chain. However, the ophthalmological examinations of her son were unremarkable. A novel COL4A5 mutation g. 4400_4400+1del, leading to an indel in exon 45 (r. 4198delins4198+2_4198+72), was detected in the patient and her son. This mutation produces a shift in the reading frame, resulting in a missense sequence of 13 codons followed by a premature stop codon. Her mother was not affected with the mutation.

Conclusions: Our report extends the phenotypic and genotypic spectrum of X-linked Alport syndrome.

Alport Syndrome (AS) is a generalized inherited disease characterized by hematuria, progressive renal failure, sensorineural deafness and ocular abnormalities [1]. X-linked AS (XLAS, OMIM 301050), resulting from mutations in the type IV collagen alpha 5 (COL4A5) gene encoding the type IV collagen α5 chain, accounts for 85% of AS. Up to now, nearly 700 COL4A5 mutations have been reported (accessed May 6, 2012). About 45% of COL4A5 mutations are missense mutations. The remaining mutations are splice site mutations, deletions, insertions, small indels, or complex rearrangements. However, these mutations are located throughout the gene without any identified mutational hot spot. The remainder of the AS patients have autosomal recessive or, rarely, an autosomal dominant inheritance (OMIM 203780,104200), both of which result from mutations in the COL4A3 or COL4A4 gene [2-4]. Diagnosis of AS relies on clinical presentation, immunohistochemical analysis of collagen α (IV) chains in skin and/or renal biopsy specimen, ultrastructural changes of the glomerular basement membrane (GBM) and genetic molecular analysis.

Ocular abnormalities may involve the cornea, iris, lens, or retina in AS [2,4], among which anterior lenticonus and the dot-and-fleck retinopathy are characteristic of AS. Colville et al. [2] reported that the dot-and-fleck retinopathy occurred in 85% of affected adult males, and anterior lenticonus in approximately 25% of all XLAS patients. However, a lower incidence rate of retinopathy (about 20%) were observed in recent large-scale cohorts [3,5,6], one of which reported a strong relationship between COL4A5 mutation categories and ocular changes in XLAS male patients [6]. Anterior lenticonus results from bulging of the lens through a thinned anterior capsule. Vertical dehiscences extending up to two thirds of the thickness of the anterior capsule were also observed under electron microscope [7-9]. Immunostaining pattern of α3 (IV) to α5 (IV) collagen chains in the anterior lens capsule ranged from decreased immunofluorescence to normal [9,10], reflecting a genetic heterogeneity [10]. Abnormal α3a4α5
type IV collagen network in the internal limiting membrane/nerve fiber layer (ILM/NFL) may be responsible for the pathogenesis of the dot-and-fleck retinopathy in AS patients [11].

Macular hole [12] and posterior lenticous [13-16] are rare ocular manifestations in AS, and few reports described the underlying mutations. Macular hole accompanied with both anterior and posterior lenticous has not previously been reported. In this study, we present a novel splice site mutation in the COL4A5 gene identified in a Chinese female patient who presented with bilateral giant macular holes and bilateral anterior and posterior lenticous.

METHODS

Patient: A pedigree of the Chinese Alport kindred is shown in Figure 1. The female proband, II-2, initially had decreased visual acuity at age 14. At age 25, laboratory investigation showed microscopic hematuria. At age 33 in 2007, she was referred to our hospital. She had normal blood pressure, normal renal function (the serum level of creatinine was 74 μmol/l, and that of urea nitrogen was 4.10 mmol/l), microscopic hematuria with mild proteinuria (0.87 g/24 h), and sensorineural hearing loss on pure-tone audiometry; electron microscopy showed irregular thinned and thickened areas of the GBM with splitting of the lamina densa (Figure 2A). The proband’s only son, III-1, presented with hematuria.
at age 3 in 2009, and indirect immunofluorescence of the epidermal basement membrane showed positive for the collagen α1 (IV) chain and negative for the α5 (IV) chain (Figure 2B,C). The proband’s parents and siblings (I-1, I-2, II-3, and II-4) had no history of microscopic hematuria and proteinuria. After obtaining informed consent, a formal ophthalmological examination was performed in the proband and her family members. Gene analysis of COL4A5 was performed in II-2, III-1 and I-2 with approval from the Ethical Committee of Peking University First Hospital. The proband denied any surgical intervention.

Ocular examination: Proband II-2 underwent detailed ophthalmologic examinations including best corrected visual acuity (BCVA), near vision test, slit lamp examination of the anterior segment under maximally dilated pupil, direct and indirect ophthalmoscopy, fundus photography, optical coherence tomography (OCT; 3D OCT-1000; Topcon, Tokyo, Japan) at her first presentation to our hospital. Individual III-1 (at the age of 5), I-1, I-2, II-3, and II-4 also underwent all the above ophthalmologic evaluations. Digital slit lamp photography was used to document the bilateral anterior and posterior lenticous found in proband II-2.

COL4A5 gene analysis: The entire coding region of COL4A5 mRNA from cultured skin fibroblast of III-1 was analyzed by using reverse transcription-polymerase chain reaction (RT–PCR) and direct sequencing as described in our previous report [17]. The COL4A5 mRNA transcripts in cultured skin fibroblasts of II-2 and III-1 were analyzed by RT–PCR which amplified a 284 bp fragment of the COL4A5 cDNA encompassing exons 45, 46 and partial sequences of exons 44 and 47. A pair of primers (F, 5′-CTC CAG GTC CTC CTG GAT TA-3′; R, 5′-GGG ACC TTG CAG GTC CTC CTG GAT TA-3′) was used.

Figure 3. Slow progression of bilateral giant macular holes. The diameters of the macular holes were about 2 disc diameter at age 28 (A, B). At age 33, when first referred to our hospital, the diameters of the macular holes had increased to about 2.5 disc diameter (C, D).
CAA TCC ATC T-3′) was designed according to the published sequence (NM_033380). The PCR mixture (per 25 μl) contained cDNA template 1 μl, 2× Taq plus Master Mix (Tiangen Biotech Co., Ltd., Beijing, China) 12.5 μl, and 5 pmol/μl of each primer 1μl. The PCR parameters were optimized as follows: an initial denaturation at 94 °C for 7 min, 35 cycles of denaturation (94 °C for 30 s), annealing (58 °C for 30 s), elongation (72 °C for 45 s), and a final elongation for 7 min at 72 °C. The PCR products were checked by electrophoresis in a 2% agarose gel and by direct sequencing. Cultured skin fibroblast from two normal males were used as controls.

To further confirm the abnormality in exon 45 detected at the cDNA level, genomic DNAs of II-2, III-1, and I-2 were amplified using the published PCR primers and conditions for exon 45 [18] and were analyzed by direct sequencing.

RESULTS
Findings on ocular examination: Proband II-2 had been diagnosed with progressive myopia in the local hospital since she first complained decreased visual acuity in both eyes at age 14. It was not until she was 28 years old that bilateral giant macular holes (about 2 disc diameter, DD) were documented in the local hospital (Figure 3A,B). When first presented to our hospital at age 33, her BCVA was 0.2 with −8.75 D sphere OU; her near vision was J2 OU; slit lamp examination of the anterior segment showed bilateral anterior and posterior lenticonus (Figure 4); fundus photography and OCT showed bilateral giant macular holes which were larger than photographed at age 28 (Figure 3C,D).

The ophthalmological examinations of III-1, I-1, I-2, II-3, and II-4 were unremarkable except that both of II-3 and II-4 were moderately myopic.

Gene analysis: As shown in Figure 5B, in III-1, direct sequencing of COL4A5 cDNA, amplified by a pair of primers 1/1’ (Figure 5A), revealed an indel in exon 45 (r. 4198delins4198+2_4198+72). Agarose gel electrophoresis showed that he had a larger sized RT–PCR product, suggestive of an insertion; as for II-2, a heterozygous pattern
of PCR products was detected (Figure 5C). It is worth noting that the mRNA expression level of the normal COL4A5 allele was higher than the mutant. Subsequent bidirectional sequencing of II-2’s RT–PCR product confirmed that she was heterozygous with one normal allele and one mutated allele (Figure 5D).

To further characterize the mutation, COL4A5 exon 45 with sequences of flanking introns were amplified by PCR from genomic DNAs of II-2 and III-1; subsequent sequence analysis demonstrated a hemizygous 2-base-pair deletion involving both the 3’ end of exon 45 and the 5’ end of intron 45 in III-1 (Figure 6A); II-2 was found to be heterozygous for the same mutation (Figure 6B). This data confirmed the result of cDNA analysis. Namely, mutation g. 4400_4400+1del (numbered according to the reference sequence defined by Zhou et al. [19]) resulted in a single base deletion at position 4198 and affected the 5’ splice site, which caused an insertion of 71-bp of intron 45 between nucleotides 4197 and 4199 of the COL4A5 mRNA (NM_ 000495). This mutation produces an shift in the reading frame, resulting in a missense sequence of 13 codons followed by a premature stop codon. According to the Human Gene Mutation database (accessed May 6, 2012), the mutation was novel. I-2’s DNA was negative for mutation g. 4400_4400+1del screen (Figure 6C).

**DISCUSSION**

According to the strict diagnostic criteria of AS proposed by Flinter et al. [20], the proband described here could be clinically diagnosed with XLAS. An identified splice site mutation in COL4A5 was sufficient to explain the development of renal disease, deafness and ocular abnormalities.

Both macular hole and posterior lenticonus are rare ocular manifestations in AS [12-16]. Bekheirnia et al. [6] reported that macular hole occurred in 1 out of 681 US male patients with XLAS and characterized the exact pathogenic mutation. Shah et al. [12] reviewed 9 patients with large macular holes and identified AS in 6 of these cases, whereas the defect in
COL4A5 gene was unknown. Posterior lenticonus usually coexist with anterior lenticonus [13-16], and no genotypic data on AS patients with posterior lenticonus is currently available. II-2 presented with not only anterior and posterior lenticonus, but also macular holes. To our knowledge, this is the first report of such rare ocular phenotype in XLAS.

II-2 had no visual complaints until 14 years old, suggesting a late adolescence or early adulthood onset of macular holes, which was in accordance with previous reports [12,21-23]. Currently, few reports have observed the dynamic evolution of macular holes, except that Shah et al. [12] documented the evolution of multiple small macular holes into a large macular hole in a male AS patient. In II-2, enlargement of the macular holes were observed from age 28 to 33, demonstrating the slowly progressive nature even in giant macular holes (2 DD in diameter). The pathogenesis of macular holes in AS patients is not clear. Dysfunction of the Bruch membrane [24] and the internal limiting membrane [12] due to abnormal type IV collagen were proposed to be involved. Although anterior lenticonus has long been recognized as a characteristic ocular manifestation of AS, posterior lenticonus has rarely been reported to be associated with AS [16]. The preferential involvement of the anterior lens capsule in AS remains to be investigated. Detailed ocular status should be monitored regularly in II-2 and III-1, which might provide further information on pathogenesis, nature history, prognosis and potential intrafamilial heterogeneity of this specific ocular phenotype.

A strong relationship has been observed between COL4A5 mutation categories and ocular changes in European and US male patients with XLAS. In the study by Jais et al. [3], the frequency of lenticonus was significantly higher in male patients with large COL4A5 deletion or small mutation resulting in premature stop codon. In the study by Bekheimia et al. [6], male patients with COL4A5 deletions or splice or truncating mutations had two- to fourfold greater odds of developing ocular abnormalities than those with missense mutations. In II-2, the identified splice site mutation in COL4A5 was predicted to produce a truncated α5 (IV) chain lacking the normal NC domain and part of the collagenous domain, which would interfere with the formation of the triple helical structure of type IV collagen molecule and the assembly of the supramolecular type IV collagen structure. As in the eye, the α5 (IV) chain is normally present in the lens capsule, Descemet, Bruch and internal limiting membranes [25], it is reasonable to infer that dysfunction of the lens capsule, Bruch and internal limiting membranes resulted from deposit of abnormal type IV collagen was responsible for this severe ocular phenotype in II-2. III-1, however, presented with no ocular abnormalities, one possible explanation is that he was too young.

This rare ocular phenotype may also be due, in part, to the X-inactivation pattern, a process ensuring only a single X is active in both the XX female and the XY male. We previously reported that the quantity of the mRNA expression level of mutant COL4A5 gene was correlated with the phenotypic severity of XLAS females [26]. A severe phenotype of two XLAS female patients was attributable to a severe skewed pattern of X-inactivation in favor of expression of the mutant COL4A5 [27,28]. Rheault et al. [29] reported that in murine XLAS, favorable X-inactivation improved survival of female carriers. Unfortunately, the difficulty to obtain the eye tissues has impeded further study of the X-inactivation pattern of II-2.

In conclusion, this report described a rare ocular phenotype in a female XLAS patient and characterized a novel splice site mutation in the COL4A5 gene, which provides new phenotypic and genotypic information on the disease. To further understand the molecular mechanisms of XLAS, a multidisciplinary strategy is recommended.

ACKNOWLEDGMENTS

The authors greatly appreciate the patient and her family for participating in this study. This work was supported by Beijing Nature Science Foundation (7102148) and Ministry of Human Resources and Social Security of the People’s
REFERENCES

1. Kashtan CE. Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol 1998; 9:1736-50. [PMID: 9727383]

2. Colville DJ, Savige J. Alport syndrome. A review of the ocular manifestations. Ophthalmic Genet 1997; 18:161-73. [PMID: 9457747]

3. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Verellen C, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schröder C, Sanak M, Krejcova S, Carvalho MF, Sauj S, Antignac C, Smeets H, Gubler MC. X-linked Alport syndrome: natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 2000; 11:649-57. [PMID: 10752524]

4. Savige J, Colville D. Opinion: Ocular features aid the diagnosis of Alport syndrome. Nat Rev Nephrol 2009; 5:356-60. [PMID: 19474829]

5. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Daham K, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schröder C, Sanak M, Carvalho MF, Sauj S, Antignac C, Smeets H, Gubler MC. X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a “European Community Alport Syndrome Concerted Action” study. J Am Soc Nephrol 2003; 14:2603-10. [PMID: 14514738]

6. Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, Schrier RW. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol 2010; 21:876-83. [PMID: 20378821]

7. Streten BW, Robinson MR, Wallace R, Jones DB. Lens capsule abnormalities in Alport's syndrome. Arch Ophthalmol 1987; 105:1693-7. [PMID: 3689194]

8. Kato T, Watanabe Y, Nakayasu K, Kanai A, Yajima Y. The ultrastructure of the lens capsule abnormalities in Alport's syndrome. Jpn J Ophthalmol 1998; 42:401-5. [PMID: 9822972]

9. Ohkubo S, Takeda H, Higashide T, Ito M, Sakurai M, Shirao Y, Yanagida T, Oda Y, Sado Y. Immunohistochemical and molecular genetic evidence for type IV collagen alpha5 chain abnormality in the anterior lenticonus associated with Alport syndrome. Arch Ophthalmol 2003; 121:846-50. [PMID: 12796257]

10. Cheong HI, Kashtan CE, Kim Y, Kleppel MM, Michael AF. Immunohistologic studies of type IV collagen in anterior lens capsules of patients with Alport syndrome. Lab Invest 1994; 70:553-7. [PMID: 8176894]

11. Savige J, Liu J, DeBuc DC, Handa JT, Hageman GS, Wang YY, Parkin JD, Votey B, Fassett R, Sarks S, Colville D. Retinal basement membrane abnormalities and the retinopathy of Alport syndrome. Invest Ophthalmol Vis Sci 2010; 51:1621-7. [PMID: 19850830]

12. Shah SN, Weinberg DV. Giant macular hole in Alport syndrome. Ophthalmic Genet 2010; 31:94-7. [PMID: 20450313]

13. Bhatnagar R, Kumar A, Pakrasi S. Alport's syndrome–ocular manifestations and unusual features. Acta Ophthalmol (Copenh) 1990; 68:347-9. [PMID: 2392916]

14. Sukhija J, Saini JS, Jain AK. Phacoemulsification and intraocular lens implantation in an Alport's syndrome patient with bilateral anterior and posterior lenticus. J Cataract Refract Surg 2003; 29:1834-6. [PMID: 14522311]

15. Vedantham V, Rajagopal J, Ratnagiri PK. Bilateral simultaneous anterior and posterior lenticus in Alport's syndrome. Indian J Ophthalmol 2005; 53:212-3. [PMID: 16137977]

16. Al-Mahmood AM, Al-Swailem SA, Al-Khalaf A, Al-Binali GY. Progressive posterior lenticus in a patient with alport syndrome. Middle East Afr J Ophthalmol 2010; 17:379-81. [PMID: 21180444]

17. Wang F, Wang Y, Ding J, Yang J. Detection of mutations in the COL4A5 gene by analyzing cDNA of skin fibroblasts. Kidney Int 2005; 67:1268-74. [PMID: 15780079]

18. Martin P, Heiskari N, Leinonen A, Tumelius T, Hertz JM, Barker D, Gregory M, Atkin C, Styrkarsdottir U, Neumann H, Springate J, Shows T, Pettersson E, Tryggvason K. High mutation detection rate in the COL4A5 collagen gene in suspected Alport syndrome using PCR and direct DNA sequencing. J Am Soc Nephrol 1998; 9:2291-301. [PMID: 9848783]

19. Zhou J, Leinonen A, Tryggvason K. Structure of the human type IV collagen COL4A5 gene. J Biol Chem 1994; 269:6608-14. [PMID: 8120014]

20. Flinter FA, Cameron JS, Chantler C, Houston I, Bobrow M. Genetics of classic Alport's syndrome. Lancet 1988; 2:1005-7. [PMID: 2902439]

21. Kaimbo K, Moussa G. Anterior lenticus, suggesting Alport syndrome. Apropos of a first case in Zaire. J Fr Ophtalmol 1992; 15:493-6. [PMID: 1294614]

22. Saika S, Hayashi Y, Miyamoto T, Yoshitomi T, Ohnishi Y. Multiple retinal holes in the macular region: a case report. Graefes Arch Clin Exp Opthalmol 2002; 240:578-9. [PMID: 12136291]

23. Rahman W, Banerjee S. Giant macular hole in Alport syndrome. Can J Ophthalmol 2007; 42:314-5. [PMID: 17392861]

24. Mete UO, Karaaslan C, Ozbilgin MK, Polat S, Tap O, Kaya M. Alport's syndrome with bilateral macular hole. Acta Ophthalmol Scand 1996; 74:77-80. [PMID: 8689488]

25. Kashtan CE. Alport syndrome. An inherited disorder of renal, ocular, and cochlear basement membranes. Medicine (Baltimore) 1999; 78:338-60. [PMID: 10499074]

26. Wang Y, Zhang H, Ding J, Wang F. Correlation between mRNA expression level of the mutant COL4A5 gene and phenotypes of XLAS females. Exp Biol Med (Maywood) 2007; 232:638-42. [PMID: 17461610]

27. Guo C, Van Damme B, Vanrenterghem Y, Devriendt K, Cassiman JJ, Marynyn P. Severe alport phenotype in a woman with two missense mutations in the same COL4A5 gene and preponderant inactivation of the X chromosome carrying the normal allele. J Clin Invest 1995; 95:1832-7. [PMID: 7706490]
28. Iijima K, Nozu K, Kamei K, Nakayama M, Ito S, Matsuoka K, Ogata T, Kaito H, Nakanishi K, Matsuo M. Severe Alport syndrome in a young woman caused by a t(X;1) (q22.3;p36.32) balanced translocation. Pediatr Nephrol 2010; 25:2165-70. [PMID: 20386926]

29. Rheault MN, Kren SM, Hartich LA, Wall M, Thomas W, Mesa HA, Avner P, Lees GE, Kashtan CE, Segal Y. X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome. Nephrol Dial Transplant 2010; 25:764-9. [PMID: 19854849]